Alaunos Therapeutics (TCRT) Restructuring Costs (2023)
Alaunos Therapeutics' (TCRT) quarterly Restructuring Costs came in at $850000.0 in Q4 2023, up 102.86% on a QoQ basis from $419000.0 in Q3 2023.
Alaunos Therapeutics (TCRT) Restructuring Costs (2023) Analysis & Trends
Alaunos Therapeutics (TCRT) has 1 years of Restructuring Costs data on file, last reported at $850000.0 in Q4 2023.
- Quarterly Restructuring Costs changed N/A year-over-year to $850000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $1.3 million (changed 0.0% YoY) and the FY2023 annual result came in at $1.3 million, changed N/A from the prior year.
- Restructuring Costs climbed to $850000.0 in Q4 2023, from $419000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $850000.0 in Q4 2023 to a low of $419000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Alaunos Therapeutics | 4.40 Mn | 4.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 850,000.00 |
| Sep 30, 2023 | 419,000.00 |